TY - JOUR
T1 - Lack of effect of gender and oral contraceptive steroids on the pharmacokinetics of (R)‐ibuprofen in humans.
AU - Knights, KM
AU - McLean, C F
AU - Tonkin, AL
AU - Miners, JO
PY - 1995/8
Y1 - 1995/8
N2 - The effects of gender and oral contraceptive steroids on the pharmacokinetics of (R)‐ibuprofen were studied in groups of healthy adult males, females and oral contraceptive steroid (OCS) using females. The values of AUC, CLpo, t1/2 and Vss, app did not differ significantly between the groups. Similarly, the percentage unbound of (R)‐ibuprofen in pooled plasma from the three groups was not statistically different. Since chiral inversion is the major determinant of (R)‐ibuprofen clearance in humans, it may be inferred from these data that gender and OCS have little or no effect on conversion of (R)‐ibuprofen to the pharmacologically active S‐ enantiomer. Moreover, it is unlikely that hormonal factors influence the activity of the human hepatic long‐chain fatty‐acid:CoA ligase, the enzyme mediating the rate limiting step of (R)‐ibuprofen inversion.
AB - The effects of gender and oral contraceptive steroids on the pharmacokinetics of (R)‐ibuprofen were studied in groups of healthy adult males, females and oral contraceptive steroid (OCS) using females. The values of AUC, CLpo, t1/2 and Vss, app did not differ significantly between the groups. Similarly, the percentage unbound of (R)‐ibuprofen in pooled plasma from the three groups was not statistically different. Since chiral inversion is the major determinant of (R)‐ibuprofen clearance in humans, it may be inferred from these data that gender and OCS have little or no effect on conversion of (R)‐ibuprofen to the pharmacologically active S‐ enantiomer. Moreover, it is unlikely that hormonal factors influence the activity of the human hepatic long‐chain fatty‐acid:CoA ligase, the enzyme mediating the rate limiting step of (R)‐ibuprofen inversion.
UR - http://www.scopus.com/inward/record.url?scp=0029123211&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2125.1995.tb05769.x
DO - 10.1111/j.1365-2125.1995.tb05769.x
M3 - Article
C2 - 8562298
AN - SCOPUS:0029123211
SN - 0306-5251
VL - 40
SP - 153
EP - 156
JO - British Journal of Clinical Pharmacology
JF - British Journal of Clinical Pharmacology
IS - 2
ER -